Presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), the data support past observations that SERDs tend to perform better in ESR1 ...
News
- SABCS: Eli Lilly's oral SERD Ember counts on Verzenio to broaden its glow - Fierce Biotech
- SystImmune, Inc. to Present Updated BL-B01D1 Data in Breast Cancer at SABCS Congress 2024
(SystImmune), a clinical-stage biotechnology company, today announced ... San Antonio Breast Cancer Symposium (SABCS) 2024, taking place on ...
- Wobble Genomics' technology demonstrates potential in accelerating precision medicine innovations
Wobble Genomics, a healthcare and biotechnology company at the forefront of long-read RNA sequencing, has presented new data at the San Antonio ...
- Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant ... - Quantisnow
... SAN ANTONIO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc ... Biotechnology: Biological Products (No Diagnostic Substances). Health Care ...
- The START Center for Cancer Research Expands its Capabilities to Support Early-Phase ...
SAN ANTONIO, Dec. 10, 2024 /PRNewswire/ -- The START Center for Cancer ... Sarepta, Biotech's Regulatory Go-Getter, Signs Standout Rare Disease Deal.